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NEAT (NATIONAL EPIRUBICIN ADJUVANT TRIAL) AND
SCTBG BR9601 (SCOTTISH CANCER TRIALS BREAST
GROUP) PHASE III ADJUVANT BREAST TRIALS SHOW A
SURVIVAL ADVANTAGE FOR SEQUENTIAL ECMF. 
Christopher J. Poole*, Helena M. Earl, Janet A. Dunn, Louise Hiller,
Sarah Bathers, David Spooner, Robert J. Grieve, Rajiv K. Agrawal,  Liz 
Foster, Chris Twelves on behalf of the NEAT Investigators and the SCTBG.
Cancer Research UK Clinical Trials Unit, Institute for Cancer Studies,
Edgbaston, Birmingham
  NEAT and SCTBG BR9601 address the role of Epirubicin in adjuvant 
chemotherapy for women with early breast cancer. NEAT (2021 eligible 
patients) compared Epirubicin (100mg/m2 x4cycles) followed by classical 
(c) CMF (x4 cycles) with cCMF (x6 cycles); SCTBG BR9601 (370 eligible 
patients)  compared Epirubicin (100mg/m2 x4 cycles) followed by iv dose 
modified 3-weekly CMF (750:50:600 x4 cycles) with iv 3-weekly CMF 
(x8cycles). Prognostic characteristics were balanced across treatments: 72% 
were node positive; 59% ≤50 years old; 58% of tumours grade 3; 57% 
>2cms; 32% ER-ve, 50% ER+ve (18%NK). For the more intensive cCMF-
containing  NEAT  regimens, median delivered dose intensity was 
93%/course, with similar myelosuppression, amenorrhoea, supportive 
treatments, treatment-related mortality rates and global Quality of Life. 
 The first pre-planned joint interim analysis is based on 309 deaths/428 
relapses or deaths (median follow-up 32 months (IQR21–45)). Despite 
lower than anticipated rates in the control arm, there is a highly significant 
benefit in favour of ECMF for both RFS (HR 0.70, 95%CI 0.58–0.85; 
p=0.0003) and OS (HR 0.64, 95%CI 0.51–0.81; p=0.0001) irrespective of 
trial, lymph node status, age and ER status. Both treatment regimens are 
tolerable, with achievable optimal dose intensities. These data add to those 
of the Overview in respect of an anthracycline advantage and augur for 
ECMF as an established standard adjuvant therapy.
CT2
RANDOMISED TRIAL OF PACLITAXEL IN COMBINATION
WITH PLATINUM CHEMOTHERAPY VERSUS PLATINUM-
BASED CHEMOTHERAPY IN THE TREATMENT OF
RELAPSED OVARIAN CANCER (ICON4/OVAR 2.2)  Jonathan
A Ledermann*, on behalf of ICON and AGO Collaborators, MRC
Clinical Trials Unit, 222 Euston Road, London NW1 2DA, UK
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PERIOPERATIVE CHEMOTHERAPY IN OPERABLE
GASTRIC AND LOWER OESOPHAGEAL CANCER: A
RANDOMISED, CONTROLLED TRIAL (THE MAGIC
TRIAL, ISRCTN 93793971). W Allum*, D Cunningham, S
Weeden on behalf of the UK NCRI Upper GI Clinical Studies
Group.  *Epsom General Hospital. 
MAGIC was designed to determine whether Epirubicin, Cisplatin and 
infused 5-FU (ECF) improves survival in operable oesophagogastric 
cancer. 
Patients with resectable oesophagogastric adenocarcinoma were 
randomised to receive perioperative chemotherapy (CSC arm) or surgery 
alone (S arm). In the CSC arm, chemotherapy consisted of three pre- and 
three post-operative cycles, 3 weeks apart, of E 50 mg/m2 IVbolus, C 
60mg/m2 in fusion and 5-FU 200mg/m2/day continuous infusion.
 Between 1994 and 2002, 503 patients (250 CSC, 253 S) were 
randomised; 74% were gastric, 15% oesophago-gastric junction and 11% 
oesophageal cancers.  In the CSC arm, 88% of patients completed pre-
operative chemotherapy, 55% commenced post-operative chemotherapy 
and 40% completed all 6 cycles.
 Resection was considered curative in 79% CSC compared with 69% S 
patients (p=0.02, χ2 test). Post-operative complications were similar (CSC 
46%, S 46%) as were deaths within 30 days (CSC 6%, S 7%). Maximum 
diameter of the resected tumour was 3cm for CSC patients and 5cm for S 
patients (p<0.001, Mann-Whitney U test). For gastric and junctional 
patients, pathological staging demonstrated 54% CSC were T1/T2 
compared with 36% S (p=0.01, χ2 test) and 80% CSC were N0/N1 
compared with 71% S (p=0.10, χ2 test).
 Thus, ECF produces an increased curative resection rate, reflecting a 
downsizing and histopathologic downstaging effect.  By April 2003, the 
number of events required for the primary outcome analysis of 
overallsurvival will be available. 
CT4
CHEMOTHERAPY AT STANDARD OR INCREASED DOSE
INTENSITY IN PATIENTS WITH OPERABLE
OSTEOSARCOMA OF THE EXTREMITY: A RANDOMISED
CONTROLLED TRIAL (ISRCTN 86294690).  Ian Lewis*,
Marianne Nooij on behalf of the European Osteosarcoma
Intergroup (EOI).  *St James’s University Hospital, Leeds.
Patients (pts) with ovarian cancer relapsing ≥ 6 months after platinum 
therapy are generally retreated with platinum-based chemotherapy.  ICON4 
(co-ordinated by MRC and Mario Negri Institute (IRFMN)) and OVAR 2.2 
(co-ordinated by the German AGO group) were parallel trials comparing 6 
cycles of platinum chemotherapy (Plat) versus paclitaxel plus Plat (Pac-
Plat) in pts relapsing with a treatment-free interval of ≥ 6 months 
(MRC/AGO), or ≥ 12 months (IRFMN).  Protocol doses were: paclitaxel, 
175mg/m2 or 185mg/m2; carboplatin, minimum AUC 5;cisplatin alone, 75 
mg/m2; cisplatin in combination, 50mg/m2.  802 patients from UK, Italy, 
Norway, Germany and Switzerland were randomised between 01/96 and 
03/02.  Data were analysed as a single trial stratified by randomising group 
(MRC, IRFMN,AGO).  Pt characteristics were similar both across the 
randomising groups and treatment arms.  By10/02, with a median follow-up 
of 34 months, 674 (84%) pts had progressed or died, with a hazard ratio 
(HR) of 0.77 in favour of Pac-Plat (p=0.006).  This translates into an 
absolute improvement in 1-year progression-free survival (PFS) of 9% 
(40% to 49%; 95% confidence interval (CI) 4%-15%).  463 (58%) pts have 
died; HR ratio is 0.77 in favour of Pac-Plat (p=0.006), which translates into 
an absolute improvement in2-year survival of 9% (50% to 59%; 95% CI 
3%-14%).  There wasno evidence that the effect of Pac-Plat is larger or 
smaller in any subgroups.  These results suggest that Pac-Plat improves 
survival and PFS in pts with ‘platinum-sensitive’ relapsed ovarian cancer.
 Previous EOI randomised trials have shown that a two-drug 
chemotherapy regimen of cisplatin and doxorubicin is an effective and 
tolerable treatment for patients with operable osteosarcoma. The aim of 
this trial was to investigate whether increasing the dose intensity of this 
regimen using granulocyte colony-stimulating factor (G-CSF) would 
improve survival in this rare disease.  
  Previously untreated patients aged 40 or under with biopsy-proven, 
non-metastatic osteosarcoma of an extremity were eligible for this trial. 
Patients were randomised between the standard two-drug regimen and 
the same regimen intensified by the addition of G-CSF.  In the standard 
arm, chemotherapy consisted of six three-weekly cycles of cisplatin 
(100mg/m2 24-hour infusion) and doxorubicin (25mg/m2/day by 4-hour 
infusion for three days).  The doses of cisplatin and doxorubicin were 
identical in the intensified arm, but cycles were given every two weeks 
intensified by G-CSF(5mcg/kg/day subcutaneous injection on days 4-13 
of the cycle).  Surgery was scheduled for week 6 in both arms.
  Between May 1993 and September 2002, 504 patients (251 standard 
arm, 253 intensified) were randomised from centres in Europe, South 
America, South Africa, Canada and Saudi Arabia. Thus this trial is one 
of the largest conducted in osteosarcoma. Analysisis planned for Spring 
2003 at which time the number of events required for the primary 
outcome analysis of overall survival will be available.
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MRC AML 12 - PAEDIATRICS.
Brenda E Gibson*, David Webb, Keith Wheatley, an behalf of 
MRC CLWP. Siebold de Graaf on behalf of DCOG
*Royal Hospital for Sick Children, Yorkhill, Glasgow G3 8SJ 
MRC AML 12 recruited 525 children between 1995 and 2002.  It
adopted the template of its preceding trial, MRC AML 10, which
provided information allowing risk stratification based on
cytogenetics and response to initial therapy.  Good risk patients – 
t(8;21), inv(16) or t(15;17) – were not eligible for allograft and no
patients received ABMT. Children were first randomised to
receive induction chemotherapy with either ADE or MAE and
thereafter randomised to receive 4 or 5 courses of treatment in
total, where the extra course was HD Ara-C and Asparaginase.  If
a donor was available, a sibling allograft (n=43) was
recommended as the final course.  
The CR rate is 92%, induction deaths 4% and 4% showing
resistance disease.  Deaths in first remission are 6% and the 5 year
relapse rate is 33%. There are no significant differences between
children receiving ADE or MAE and no advantage for five blocks
of treatment over four.  Within risk groups survival from CR is
superior to that of AML 10 which cannot be explained by the
randomised comparisons.  43 children have received an alloBMT,
and donor versus no donor comparisons within the standard and
poor risk groups do not show any survival differences, although
numbers are small. 
Risk group stratification based on cytogenetics continues to
predict outcome.  The limit to which conventional chemotherapy,
both during induction and consolidation, can further improve
outcome may have been reached and new approaches need to be
explored. 
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RANDOMISED TRIAL OF IFOSFAMIDE, CARBOPLATIN 
AND ETOPOSIDE WITH MID-CYCLE VINCRISTINE (ICE-V) 
VERSUS STANDARD CHEMOTHERAPY (C) IN PATIENTS 
WITH SMALL CELL LUNG CANCER (SCLC) AND GOOD 
PERFORMANCE STATUS (PS) (MRC LU21) P. Clark, on 
behalf of LU21 collaborators, MRC Clinical Trials Unit, UK
Patients with SCLC and good PS should be offered intensive 
treatment aimed at prolonging survival and achieving cures. 
Etoposide, vincristine, ifosfamide, and carboplatin have been 
shown to be active. MRC LU21 trial is comparing 6 cycles of ICE-
V (day 1: i.v. ifosfamide 5 g/m
2, carboplatin 300 mg/m
2, etoposide 
120 mg/m
2; day 2: i.v. etoposide 120 mg/m
2; day 3: oral etoposide 
240 mg/m
2; day 14: i.v. vincristine 1.0 mg/m
2), at 4-week 
intervals, versus 6 cycles of C at 3-week intervals. Recommended 
C regimens were: CDE (day 1: i.v. cyclophosphamide 1 g/m
2, 
doxorubicin 40 mg/m
2, etoposide 120 mg/m
2; day 2: i.v. etoposide 
120 mg/m
2; day 3: oral etoposide 240 mg/m
2), and PE (day 1: i.v. 
cisplatin 80 mg/m
2, etoposide 120 mg/m
2; day 2: i.v. etoposide 
120 mg/m
2; day 3: oral etoposide 240 mg/m
2).  402 (202 ICE-V, 
200 C) patients were randomized. Patients characteristics were 
well balanced; median age 62 years, WHO PS 0-1 in 87%, limited 
disease in 87% of patients. 74% ICE-V and 83% C patients 
completed 4 or more cycles of chemotherapy. ICE-V compared 
with C patients experienced similar moderate or severe alopecia, 
lethargy, breathlessness, anorexia, and nausea; less mucositis, but 
more septicemia and bleeding. Response rates for ICE-V and C 
were 83% and 81%. 307 (76%) patients have died. The HR for 
survival was 0.77 (95% CI 0.62, 0.97, p = 0.026,) in favor of ICE-
V. Median survival was 15.1 (ICE-V) and 11.6 (C) months, and 1-
year survival rates were 54% and 45%. In summary, ICE-V 
improved survival compared with standard chemotherapy in 
patients with SCLC and good PS with acceptable toxicity. 
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